Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$321.43MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alexandria Forbes
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 393
- Beta
- 1.27
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.41
Financials
Revenue
$321.43M+40849.1%Net Income
$160.72MEBITDA
$323.02MFree Cash Flow
$-36.53MEPS (diluted)
$1.71Shares Outstanding (diluted)
93.81M+387.6%Operating Expenses
$69.84MCash & Debt
$143.17MReturn of Capital
$0.00Revenue by Segment (annual)
$81.39MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $81.39M | $-114.20M | $-1.42 |
| 2024 | $33.28M | $-147.79M | $-2.12 |
| 2023 | $14.02M | $-84.03M | $-1.49 |
| 2022 | $15.92M | $-129.62M | $-2.87 |
| 2021 | $37.70M | $-79.56M | $-1.80 |
| 2020 | $15.56M | $-57.99M | $-1.43 |
| 2019 | $13.29M | $-54.75M | $-1.58 |
| 2018 | $0.00 | $-82.87M | $-4.37 |
| 2017 | $0.00 | $-31.04M | $-3.62 |
| 2016 | $0.00 | $-19.49M | $-1.01 |
Valuation
MGTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·13d ago·Neutral
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.
View source ↗ - Newszacks.com·53d ago·Neutral
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share a year ago.
View source ↗ - Newsprnewswire.com·55d ago·Negative
Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.46 per share
Typical surprise -4.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$1.71 vs $-0.46beat
- Thu, May 14$-0.57 vs $-0.43miss
- Thu, Mar 26$0.19 vs $-0.60beat
- Thu, Nov 13$-0.62 vs $-0.50miss
- Thu, Aug 14$-0.48 vs $-0.52beat
- Tue, May 13$-0.51 vs $-0.38miss
Estimates and results for MGTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MGTX officers and directors.
- Bought
- —
- Sold
- $5.2m
0 trades
13 trades
- Forbes Alexandriasold
- Giroux Richardsold
- Naylor Stuartsold
- Naylor Stuartsold
- Forbes Alexandriasold
- Giroux Richardsold
- Naylor Stuartsold
- Forbes Alexandriasold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MGTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.